Rate Video

ASCO 2020 | Axitinib plus pembrolizumab in advanced RCC

Michael Atkins • 26 May 2020

Genitourinary Cancer Kidney Cancer Axitinib Pembrolizumab

Michael Atkins, MD, of Georgetown University, Washington, DC, reports long-term efficacy and safety from a phase Ib study investigating the combination of axitinib and pembrolizumab in advanced renal cell carcinoma patients. This video was recorded via an online conference call with the Video Journal of Oncology (VJOncology).

What's the best option in the treatment of melanoma?

Michael Atkins • 8 Sep 2017

Combining immunotherapy with VEGF inhibitors to treat kidney cancer

Michael Atkins • 8 Feb 2018

The agents at the forefront of kidney cancer treatment

Michael Atkins • 8 Feb 2018

Combination pembrolizumab and reduced-dose ipilimumab: how low can you go?

Michael Atkins • 8 Sep 2017

Related Videos

STARTAR: one-year follow-up results

Tian Zhang • 17 Feb 2021

Biomarker analysis of olaparib with or without cediranib in mCRPC

Rana McKay • 17 Feb 2021

INTACT: safety results of CRT with and without atezolizumab in MIBC

Parminder Singh • 16 Feb 2021

Combinatorial biomarkers predict responses to ICI in mUC

Sangeeta Goswami • 16 Feb 2021